Higher us branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs

Health Affairs

Volumn 32, Issue 4, 2013, Pages 753-761

  Kanavos, Panos ^a   Ferrario, Alessandra ^a   Vandoros, Sotiris ^a   Anderson, Gerard F ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANDNAME DRUG; DRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG COST; DRUG MARKETING; PRESCRIPTION; UNITED STATES;

AUSTRALIA; CANADA; DRUG COSTS; DRUG INDUSTRY; FRANCE; GERMANY; GREAT BRITAIN; HEALTH EXPENDITURES; HUMANS; PRESCRIPTION DRUGS; SWITZERLAND; UNITED STATES;

EID: 84877964537     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0920     Document Type: Article

References (23)

1. Danzon PM, Chao LW. Crossnational price differences for pharmaceuticals: how large, and why? J Health Econ. 2000;19:159-95.
2. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood). 2003;22:w3- 521-36. DOI: 10.1377/hlthaff.w3 .521.
3. Kanavos P, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ Policy Law. 2011;6(3): 337-67.
4. UK Department of Health. The pharmaceutical price regulation scheme: tenth report to Parliament. London: The Department; 2009 Dec.
5. Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ. 1992;35(2): 331-50.
6. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Aff (Millwood). 2008;27(1):221-33.
7. Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy. 2008;23(55): 499-544.
8. Regan L. Generic entry, price competition, and market segmentation in the prescription drug market. International J Industr Org. 2008; 26(4):930-48.
9. Suh DC, Manning WG Jr, Schondelmeyer S, Hadsall RS. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res. 2000;35(2): 529-47.
10. Wiggins S, Maness R. Price competition in pharmaceuticals: the case of anti-infectives. Econ Inq. 2004; 42(2):247-63.
11. Frank R, Salkever D. Generic entry and pricing of pharmaceuticals. J Econ Manage Strat. 1997;6(1): 75-90.
12. IMS Health. Guide to pack prices on IMS Midas Quantum. Fairfield (CT): IMS Health; 2010.
13. World Bank. Inflation, GDP deflator (annual %) [Internet]. Washington (DC): World Bank; [cited 2013 Mar 5]. Available from: http://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG
14. To access the Appendix, click on the Appendix link in the box to the right of the article online.
15. Danzon PM. Making sense of drug prices. Regulation. 2000;23(1): 56-63.
16. Medicaid.gov. Medicaid Drug Rebate Program [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [last updated 2013 Feb 14; cited 2013 Mar 5]. Available from: http://www.medicaid.gov/Medicaid-CHIPProgram-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html
17. IMS Health. IMS Midas Quantum data elements, measures and statistics. Fairfield (CT): IMS Health; 2010.
18. This is done with the Paasche index, which takes into account each country's consumption levels and adjusts prices by volume in each country.
19. Kanavos P, Schurer W, Vogler S. The pharmaceutical distribution chain in the European Union: structure and impact on pharmaceutical prices [Internet]. Brussels: European Commission, DG Enterprise; 2011 Mar [cited 2013 Mar 5]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf
20. Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood). 2006; 25(5):1353-62.
21. Willis M, Persson U, Zoellner Y, Gradl B. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden. Appl Health Econ Health Policy. 2010;8(6):377-86.
22. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: European Commission, DG Enterprise; forthcoming.
23. Healthcare Products Pricing Committee. Healthcare Products Pricing Committee: annual report 2010 [Internet]. Paris: The Committee; 2011 [cited 2013 Mar 20]. Available from: http://www.sante.gouv.fr/IMG/pdf/Rapport_annuel_2010_Final_EUK-v_graph.pdf